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Background. Low-carbohydrate (LC) and high-fat, low-carbohydrate (HFLC) dietary
preparations may enhance
18F-FDG-PET-based imaging of small, inﬂamed structures near the
heart by suppressing myocardial FDG signal. We compared myocardial
18F-FDG uptake in
patients randomized to LC, HFLC, and unrestricted (UR) preparations prior to
18F-FDG-PET.
Methods and Results. We randomized 63 outpatients referred for oncologic
18F-FDG-PET
to LC, HFLC, or UR dietary preparations (1:1:1 allocation) starting the evening before PET.
After eating dinner according to instructions, UR and LC patients fasted until FDG injection
(mean time 745 minutes for UR, 899 minutes for LC), and HFLC patients drank a fatty drink
60-70 minutes prior to FDG injection. Attenuation-corrected PET imaging was performed 60
minutes after FDG administration. Maximal myocardial standard uptake values (MyoSUVmax)
were systematically measured in axial view and compared between the three groups. Using UR
patients as reference, mean MyoSUVmax was lower in LC patients (3.3 ± 2.7 vs 6.2 ± 5.2,
P 5 .03) but not in HFLC patients (5.5 ± 4.2, P 5 .63). Ratios of MyoSUVmax to liver SUVmax,
calculated to control for background uptake, were not signiﬁcantly different amongst the
groups (1.9 ± 2.1 LC, 2.6 ± 2.3 HFLC, 3.6 ± 3.5 UR).
Conclusion. In this small randomized controlled trial using UR diet as reference, LC
dietary preparation followed by extended fasting resulted in signiﬁcant myocardial uptake
suppression. (J Nucl Cardiol 2010;17:286–91.)
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INTRODUCTION
A major obstacle in using
18F-FDG to image struc-
tures adjacent to the heart rests with the myocardium,
which can signiﬁcantly interfere with visualization by
exhibiting high FDG uptake.
1,2 Control of this unwanted
uptake can potentially improve the use of
18F-FDG-PET
for identifying thoracic diseases such as cardiac sarcoid-
osis and malignancies neighboring or inﬁltrating the
cardiac chambers. In addition, reducing artifact from
high myocardial FDG signal has become important as
investigators have garnered increasing interest in nonin-
vasive detection of the inﬂamed, rupture-prone
3-6 sub-
centimeter coronary artery plaque with
18F-FDG, based
on the radionuclide’s prior success with large artery
inﬂammation.
7-10
Dietary modiﬁcation appears to affect myocardial
18F-FDG metabolism. Lum et al showed that carbohy-
drate restriction prior to PET reduced artifact from
myocardial
18F-FDG uptake.
11,12 Recently, Williams
and Kolodny published an observational, historical-
control study in which patients who consumed a very
high-fat, low-carbohydrate diet before FDG injec-
tion exhibited markedly reduced maximal myocardial
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28618F-FDG uptake.
13 The same group has subsequently
reported preliminary success in using this technique to
facilitate
18F-FDG-PET imaging of coronary artery
inﬂammation.
14 Although encouraging, these ﬁndings
were not from prospective, controlled studies. To sys-
tematically address the impact of diet on myocardial
glucose metabolism, we conducted a prospective com-
parison of myocardial FDG uptake in patients
randomized to unrestricted (UR), low-carbohydrate
(LC), high-fat and low-carbohydrate (HFLC) dietary
preparations.
MATERIALS AND METHODS
Patient Population and Dietary Assignment
Using computerized randomization, we assigned 63 out-
patients without exclusion criteria (acute inﬂammatory
gallbladder or pancreatic disease, serum triglycerides
[600 mg/dL, or solid food dysphagia) referred to Cedars-
Sinai Medical Center for whole-body
18F-FDG-PET to one of
3 pre-scan dietary plans: UR, LC, or HFLC. Reason for referral
was cancer staging in 58 patients and lung mass evaluation in
5. The study was approved by the Cedars-Sinai Medical Center
institutional review board.
A study investigator gave detailed instructions by phone
and in print to each patient. UR patients were instructed to eat
a typical meal without restrictions in the evening prior to PET,
then fast for at least 6 hours prior to
18F-FDG injection
(patients could thus eat breakfast, as long as the meal was 6
hours or more beforehand). LC patients were instructed to eat a
dinner containing\5 g of carbohydrates in the evening prior to
PET, after which they should fast until
18F-FDG injection.
HFLC patients were instructed to eat a dinner containing[35 g
of fat and\5 g of carbohydrates in the evening prior to PET,
then fast until 60-70 minutes prior to
18F-FDG administration,
at which time they would drink a 250 mL liquid mixture of
45 mL of RESOURCE Benecalorie
 (a low-residue, no-car-
bohydrate calorie supplement containing 33 g of fat, 91% of
which is unsaturated; Novartis Medical, Basel, Switzerland),
sucralose-based Crystal Light
 ﬂavoring (Kraft Foods,
Northﬁeld, IL), and water. Benecalorie was chosen because it
was a fatty-acid supplement that did not require large-volume
preparation, could be consumed quickly, and was easy to
implement. All patients were instructed to avoid exercise and
caffeine for at least 24 hours prior to and to record foods
consumed within 18 hours before
18F-FDG injection. Written
instructions for LC and HFLC patients also listed appropriate
and inappropriate food items.
18F-FDG-PET Imaging Protocol
Dose of intravenous
18F-FDG was calculated based on
body mass, using a reference of 370 MBq for 65 kg and not
exceeding 555 MBq. Insulin was not used to control blood
glucose prior to FDG injection. If the requested PET scan
included diagnostic computed tomography (CT), thin oral
barium contrast without any ﬂavoring agent was given. After
administration of
18F-FDG, patients rested in a quiet room for
60 minutes. CT and PET images were then acquired in a
Gemini PET/CT scanner (Philips Healthcare, Bothell,
Washington). While the patient breathed normally, CT imag-
ing from the eyes to the mid thighs were performed with the
16-slice multi-detector scanner using the following parameters:
0.5 seconds per rotation, 100 mA tube current, 120 kVp tube
voltage, 5 mm slice thickness, and 4.25 mm slice interval. PET
images were acquired using4 mm slice thickness and 5 minutes
per bed position for the area of interest and 3 minutes per bed
position for all other areas (9 total bed positions for a typical
scan). Acquired images were iteratively reconstructed with
CT-based attenuation correction.
PET Image Analysis
All reconstructed, attenuation-corrected PET images
were sent to a Sun Microsystems workstation (Santa Clara,
CA) and evaluated using the Philips Scintigraph software
(Bothell, Washington). An experienced, blinded reader
assessed each study to determine image quality and generate
clinical interpretations. A separate analysis was done by a
study investigator (V.C.) to speciﬁcally quantify myocardial
18F-FDG uptake. For scans in which myocardial uptake
appeared uniform, maximal standard uptake value (SUVmax)
was obtained by drawing a region of interest around the entire
visible left ventricle in axial view, at the level of the lateral
papillary muscle. If the papillary muscle was not visible, the
reader visually selected the axial slice containing the largest
cardiac footprint. If myocardial uptake appeared heteroge-
neous, the region of interest was drawn in the axial view
containing the highest visual uptake. In addition, SUVmax
were obtained from representative areas in the right lung apex
and the liver dome that did not exhibit abnormal activity—
these areas served as controls.
Statistical Methods
Based on work from Lum et al,
11,12 we estimated a
reduction of at least 3.0 in mean myocardial SUVmax with
either LC or HFLC diet, compared to UR. Using a two-sided a
of 0.05 and b of 0.20, 21 patients per group would provide
82% power to detect this estimated difference.
All categorical variables were described as frequencies
and percents. Group comparisons of categorical variables were
made using Pearson’s chi-squared test or Fisher Exact test,
where appropriate. Continuous variables were described as
mean ± standard deviation. Comparisons of continuous vari-
ables between any 2 groups were made with the Student’s t-test
and amongst all 3 groups were made using analysis of variance
(ANOVA), with Tukey and Dunnett post-hoc testing whenever
there were statistically signiﬁcant differences. For all analyses,
differences with a P-value \.05 were considered signiﬁcant.
All statistical analyses were performed using Analyze-It soft-
ware, version 2.10 (Leeds, UK).
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As shown in Table 1, randomization resulted in 3
similar groups. Neither of the patients with diabetes (one
in UR and one in LC) used insulin. Frequencies of beta-
blocker use, which may affect myocardial glucose
metabolism, were similar. Food diary review indicated
full adherence to diet assignment for all UR and LC
patients. Two UR patients ate breakfast on the day of
PET (fasting times were 360 and 390 minutes). The
remaining 19 UR patients and all 21 LC patients fasted
after dinner until
18F-FDG injection. All UR patients
reported eating[5 g of carbohydrates and\35 g of fat
in the meal prior to
18F-FDG injection. All LC and all
HFLC patients reported restricting carbohydrate intake
to \5 g in the dinner prior to
18F-FDG injection. For
those assigned to HFLC diet, estimated fat consumption
during dinner prior to PET was \35 g in 8 patients
(38%), and all drank the Benecalorie-based mixture.
Mean fasting time before
18F-FDG injection was sig-
niﬁcantly shorter for HFLC patients (61 minutes vs 745
minutes for UR and 899 minutes for LC, P\.001).
Ranges of myocardial SUVmax were 1.2 to 16.3 for
UR, 1.0 to 10.2 for LC, and 1.4 to 15.2 for HFLC diets
(Figure 1). Compared to UR patients, mean myocardial
SUVmax was signiﬁcantly reduced in LC patients
(3.3 ± 2.7 vs 6.2 ± 5.2, 95% conﬁdence interval 0.32 to
5.48, P = .03) but not in HFLC patients (5.5 ± 4.2, 95%
conﬁdence interval -2.25 to 3.65, P = .63). Seventeen
(81%) LC, 12 (57%) HFLC, and 13 (62%) UR patients
met the suggested criterion of successful suppression:
myocardial SUVmax B 5.0.
14 When myocardial SUVmax
was divided by liver lobe SUVmax to account for
Table 1. Demographics of study population (n = 63)*
Unrestricted
(UR)
Low-carbohydrate
(LC)
High-fat and
low-carbohydrate
(HFLC) P-value
Age (years) 56 ± 16 61 ± 15 62 ± 14 NS
BMI (kg/m
2) 2 6±5 2 4±4 2 5±5 N S
Female 13 (62) 14 (67) 14 (67) NS
Diabetes 1 (5) 1 (5) 2 (10) NS
Dyslipidemia 4 (19) 5 (24) 6 (29) NS
Prior MI 0 (0) 0 (0) 0 (0) NS
Prior CABG 0 (0) 0 (0) 0 (0) NS
Prior PCI 0 (0) 0 (0) 2 (10) NS
Beta-blocker use 4 (19) 4 (19) 5 (24) NS
Cancer staging as
indication for PET
20 (95) 20 (95) 18 (86) NS
Fasting time before
18F-FDG (min)
745 ± 159 899 ± 149 61 ± 21 \0.001

18F-FDG dose (MBq) 466 ± 56 429 ± 70 426 ± 78 NS
BMI, Body mass index; MI, myocardial infarction; CABG, coronary artery bypass grafting; PCI, percutaneous coronary intervention;
PET, positron-emission tomography; FDG, ﬂuorodeoxyglucose; NS, not signiﬁcant.
*Where appropriate, results are shown as mean ± standard deviation or number and percentage (in parenthesis).
Signiﬁcant for comparison amongst all 3 groups, for LC vs UR, and LC vs HFLC.
Figure 1. Distribution of maximal myocardial
18F-FDG
uptake by dietary assignment (LC, Low-carbohydrate; HFLC,
high-fat and low-carbohydrate; UR, unrestricted), as measured
by standard uptake value (SUVmax). LC patients had signif-
icantly lower mean SUVmax than UR patients (P = .03).
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value (1.9 ± 2.1), but this was not statistically signiﬁ-
cant compared to other preparations. No signiﬁcant
difference in mean myocardial SUVmax was found
between HFLC patients who consumed\35 or C35 g fat
for dinner (6.0 ± 4.3 vs 5.2 ± 4.3, P = .66). Mean
SUVmax of the right lung apex and liver lobe were
similar for all groups. Comparisons of mean SUVmax
measured from all regions of interest are detailed in
Table 2. Figure 2 shows images from the 7 cases with
highest myocardial SUVmax from each diet group.
DISCUSSION
LC and HFLC dietary preparations aim to diminish
myocardial
18F-FDG uptake by providing the myocar-
dium increased access to fatty acids to reduce glucose-
based metabolism.
15-19 Our randomized trial found that,
compared to UR diet, a simple LC diet followed
by extended fasting effectively reduced myocardial
18F-FDG uptake, while the addition of fatty-acid loading
did not achieve a signiﬁcant reduction. These results
suggest that LC may be preferable to HFLC dietary
preparation for myocardial
18F-FDG suppression.
Besides the lack of signiﬁcant myocardial
18F-FDG
signal suppression in this trial, fatty acid loading may be
more difﬁcult for patients to perform and may not be
well-received by particularly diet-conscious patients.
Our ﬁndings differ from observations in two recent
publications from the Beth Israel Deaconess Medical
Center. These studies indicated improved myocardial
18F-FDG uptake suppression with a HFLC diet when
compared to standard ‘‘fasting’’ preparations.
13,14 A
large portion of the difference can be attributed to the
mean myocardial SUVmax of 3.3 in our LC patients,
which was markedly lower than the 8.8 reported by
Williams and Kolodny, who studied a similar population
under a similar fasting protocol.
13 In addition, myocar-
dial
18F-FDG uptake in our HFLC patients (mean
SUVmax of 5.5) was higher than the 3.9 reported by
these authors.
13 While presence of type II error was
possible (our study design had a power of 80%), sig-
niﬁcant variability in the control of myocardial
18F-FDG
uptake with fatty-acid loading remains the likely
explanation. In the follow-up study from the Beth Israel
Deaconess investigators to prospectively apply their
fatty-acid loading protocol for coronary arterial imaging
(Wykrzykowska et al), the outcome was not as impres-
sive as initially reported
14: mean myocardial SUVmax
was 7.7 and 15 of 31 (48%) patients had recorded
myocardial SUVmax[5.0. Myocardial glucose meta-
bolic activity in these patients was likely elevated in part
due to high coronary artery disease burden—26 of 32
patients had abnormal results on invasive coronary
angiography and 6 had prior myocardial infarctions.
There are at least two potential explanations for the
myocardial activity suppression we observed in LC
patients. First, in addition to carbohydrate restriction,
prolonged fasting may have helped our patients maxi-
mize free fatty acid generation from triglyceride
cleavage.
16,20 Mean duration of fasting in our LC
patients was 899 minutes; all except 1 fasted for at least
720 minutes. In the protocol described by Williams and
Kolodny, some patients received instructions to fast for
at least 240 minutes prior to
18F-FDG administration,
13
and this may have been insufﬁcient to induce optimal
circulating fatty acid levels. Second, patients in our
trial received more thorough dietary counseling than in
real-life settings, contributing to very high rates of full
diet assignment adherence and likely helping to opti-
mize results in our LC patients.
Several potential reasons for why our HFLC prep-
aration did not result in signiﬁcant myocardial
18F-FDG
uptake suppression should be mentioned. The time we
Table 2. Maximal standard uptake value (SUVmax) measures of
18F-FDG uptake by dietary assignment*
Low-carbohydrate
(LC)
High-fat and
low-carbohydrate
(HFLC)
Unrestricted
(UR) P-value
Right lung apex 0.6 ± 0.7 0.6 ± 0.2 0.6 ± 0.3 NS
Liver lobe 2.1 ± 0.7 2.3 ± 0.6 2.0 ± 0.5 NS
Myocardium 3.3 ± 2.7 5.5 ± 4.2 6.2 ± 5.2 0.03

Number with SUVmax B 5.0 17 (81%) 12 (57%) 13 (62%) NS
Myocardial SUVmax/liver
SUVmax
1.9 ± 2.1 2.6 ± 2.3 3.6 ± 3.5 NS
Number with ratio B1.0 13 (62%) 8 (38%) 9 (43%) NS
*Where appropriate, results are shown as mean ± standard deviation or number and percentage.
Signiﬁcant for LC vs UR.
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18F-FDG
injection (mean of 61 minutes) may have been too brief
to capture peak circulating triglyceride levels.
21 The
sucralose-based sweetener we used to ﬂavor the fatty
drink could have adversely affected myocardial fatty
acid metabolism. In addition, we could not verify whe-
ther fatty acid consumption based on our HFLC protocol
met or exceeded the quantity necessary for optimal
loading. Overloading the myocardium with fatty acids
may adversely increase myocardial oxygen consump-
tion, potentially prompting an unintended secondary
increase in glucose metabolism, as shown in multiple
prior experiments.
22-25
Predictable control of myocardial
18F-FDG uptake
is important when using PET to detect lesions close to
the heart; these include noncardiac thoracic pathology
and diseases of speciﬁc cardiac structures. In particular,
prominent myocardial FDG signal can greatly hinder
investigational techniques to visualize coronary vascu-
lature and coronary arterial plaque inﬂammation. For
this application, adequate suppression depends on both
the myocardium and multiple characteristics of the tar-
get coronary artery, such as its location, motion, distance
to the myocardium, and intensity of
18F-FDG uptake.
Although a SUVmax threshold of [5.0 has been sug-
gested to indicate insufﬁcient suppression,
14 true criteria
for adequate suppression likely vary by individual and
have yet to be systematically deﬁned. In the absence of
this deﬁnition, the amount of myocardial signal vari-
ability we observed (e.g., 4 LC patients (19%) and 9
HFLC patients (43%) had myocardial SUVmax[5.0)
denotes the need to improve the precision of any diet-
based approach for controlling unwanted myocardial
18F-FDG uptake.
Our study has several limitations. The entire study
population underwent
18F-FDG-PET for suspected or
conﬁrmed oncologic disease, not coronary or cardiac
disease. Hence, these patients may pose some difference
in myocardial glucose metabolism compared to patients
with coronary artery disease, particularly those with
active myocardial ischemia. To date, FDG-based imag-
ing for coronary artery disease is experimental and not
used clinically; we chose not to enroll patients referred
for
18F-FDG-based viability assessment for the concern
that the clinically important test accuracy characteristics
may be altered by changes in dietary preparation. We
did not collect lipid proﬁle and glucose laboratory data
to conﬁrm patient history. We did not ascertain serum
triglyceride changes to verify peak effect of the high-fat
drink. Adherence to dietary instructions was based on
self-report. Our technique of measuring myocardial
SUVmax was biased towards reporting the ‘‘worst-case’’
scenario and was more prone to variability and noise
than whole-heart sampling. We chose this design to be
conservative about quantifying myocardial uptake sup-
pression. Additional interventions that may impact
myocardial glucose metabolism, such as peri-imaging
beta-adrenergic receptor blockade, were not evaluated.
CONCLUSION
In this randomized controlled trial, a low-carbohy-
drate diet with extended fasting resulted in suppression
Figure 2. Representative images from 7 patients with the
highest maximal myocardial standard uptake value (SUVmax)
from each diet plan (LC, Low-carbohydrate; HFLC, high-fat
and low-carbohydrate; UR, unrestricted). In all cases, the
myocardium exhibits greater uptake than the liver and
mediastinum. Only LC dietary preparation resulted in patients
with SUVmax\5.0 in this group (the top 3 examples in the
leftmost column). The visual impression that not all myocardial
uptake appeared to increase in correspondence to increasing
SUVmax (e.g., the LC patient with SUVmax of 7.9) is because
image contrast has been individually adjusted to show
neighboring structures.
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18F-FDG uptake during PET. Low-car-
bohydrate diet followed by extended fasting prior to
18F-FDG injection should be considered a useful pro-
tocol for the purpose of developing
18F-FDG-PET to
investigate coronary arterial inﬂammation.
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